Select Studies Reporting Survival in G3 NENs After Treatment with PRRT, 2016 and 2018
| Study | Total no. patients (N) | N: Ki-67 or differentiation | Tumor primary site | PRRT type administered | PRRT dose reported | Outcome |
| Thapa et al. 2016 (33) | 50 | 3: Ki-67 > 20% | 2 panc, 1 rectal, or 2 unknown primary | 177Lu-DOTATATE (at least 3 cycles) | 5.55 GBq at 12- to 16-wk intervals | Responders: 2/3 G3, 1/2 poorly diff, 3/5 total |
| 2: poorly diff | ||||||
| Nilica et al. 2016 (40) | 66 | 7: Ki-67 > 20% | Panc, GI, lung, unknown | 90Y-DOTATOC first line; 177Lu-DOTATATE if <2 cm or retreatment (3–4 cycles) | 3.7 GBq 90Y. 7.4 GBq 177Lu at 10- to 14-wk intervals | No specific comment |
| Cycles 2–4 included radiosensitizing chemo: 5FU or capecitabine, or capecitabine temozolomide in pancreatic | ||||||
| Zhang et al. 2018 (29) | 69 | 69: Ki-67 ≥ 20% | 46 panc, 11 unknown, 6 small bowel, 3 stomach, 3 rectal | 177Lu (median number of cycles not mentioned) | Median per cycle: 4.5 GBq | Median PFS of 9.6 mo, median OS of 19.9 mo |
| 90Y (median number of cycles not mentioned) | Median per cycle: 3.2 GBq | Ki-67 ≤ 55%, median PFS of 11 mo, OS of 22 mo | ||||
| Ki-67 > 55%, median PFS of 4 mo, OS of 7 mo | ||||||
| At 3 mo: 34/69 with PR, 15/69 with stable disease, 20/69 with PD | ||||||
| Nicolini et al. 2018 (30) | 33 | 28: Ki-67 ≥ 20% | 20 panc, 5 small bowel, 2 stomach, 1 large bowel | 177Lu (in 4–5 cycles) | Median cumulative activity: 21.5 GBq at 6- to 8-wk intervals | Overall median PFS of 23 mo, median OS of 59.9 mo |
| 5: Ki-67 of 15%–20% | 3 panc, 2 small bowel | Median PFS for Ki-67 ≤ 35% of 26.3 mo vs. 6.8 mo for Ki-67 > 35% | ||||
| 14: poorly diff | 2/33 patients with PR; 21/33 patients with stable disease |
Panc = pancreatic; GI = gastrointestinal; diff = differentiated; PR = partial response; PD = progressive disease; In = indium; CI = confidence interval.